Phase II Study of Azacytidine Followed by GM-CSF in Patients With Low- or Intermediate-1- Risk Myelodysplastic Syndrome (MDS).

Trial Profile

Phase II Study of Azacytidine Followed by GM-CSF in Patients With Low- or Intermediate-1- Risk Myelodysplastic Syndrome (MDS).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2013

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Granulocyte macrophage colony stimulating factor; Granulocyte macrophage colony stimulating factor
  • Indications Myelodysplastic syndromes
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Apr 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Mar 2012 New source identified and integrated (M.D. Anderson Cancer Center record).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top